Company Name, Ticker, Competitors, else..

Climb Bio Inc (NASDAQ: CLYM)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Climb Bio Inc 's

Name: Climb Bio Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CLYM Sales vs. its Competitors Q2 2026

Comparing the current results to its competitors, Climb Bio Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 24.91 %, recorded in the same quarter.

• List of CLYM Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Climb Bio Inc , faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<< CLYM Stock Performance Comparisons

Climb Bio Inc 's Comment on Competition and Industry Peers

The company faces competition for its products budoprutug and CLYM116. Competitors may develop similar technologies independently outside the scope of the company's issued patents, which could limit the company's ability to maintain its competitive position. Patent protection may be limited due to expiration or enforceability issues, and the company may be unable to secure exclusive licenses, potentially allowing competitors access to the same technologies. Legal challenges to patents may also affect the company's ability to commercialize its products.

<< See the full list of CLYM competitors

*Market share is calculated based on total revenue.

CLYM's Stock Performance relative to its Competitors

Publicly Traded Peers of Climb Bio Inc

Blue Water Vaccines Inc
Share Performance

-83.16%

One Year

Blue Water Vaccines Inc

Profile

Blue Water Biotech Inc's business model involves leveraging biotechnology to develop and offer innovative solutions for various industries.

More about Blue Water Vaccines Inc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 0.404 mill.	$ 0.646 mill.	$ -8.698 mill.

Opus Genetics Inc
Share Performance

+18.58%

30 Days

Opus Genetics Inc

Profile

Opus Genetics develops gene therapies for inherited retinal diseases and other ophthalmic disorders.

More about Opus Genetics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 483.407 mill.	$ 9.856 mill.	$ -114.997 mill.

Kineta Inc
Share Performance

+1.85%

This Quarter

Kineta Inc

Profile

Kineta, Inc. conducts its business primarily through Private Kineta's operations following a merger.

More about Kineta Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 4.336 mill.	$ 0.500 mill.	$ -8.463 mill.

Madrigal Pharmaceuticals Inc
Share Performance

+8.39%

This Quarter

Madrigal Pharmaceuticals Inc

Profile

Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.

More about Madrigal Pharmaceuticals Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 15,507.959 mill.	$ 1,132.490 mill.	$ -309.437 mill.

Mira Pharmaceuticals Inc
Share Performance

+4.84%

30 Days

Mira Pharmaceuticals Inc

Profile

Mira Pharmaceuticals Inc's business model is focused on the development and sale of pharmaceutical products, with a particular emphasis on research and innovation in the healthcare industry.

More about Mira Pharmaceuticals Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 32.601 mill.	$ - mill.	$ -9.480 mill.

56 more competitors available

Sources: Climb Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Wednesday, September 9, 2026 12:10 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Climb Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.